Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: J Biomol Screen. 2012 Jun 29;17(9):1211–1220. doi: 10.1177/1087057112452138

Figure 2.

Figure 2

National Institutes of Health (NIH) Clinical Collection 2 high-content pilot screen. (A) Fractions of cells positive for CK5Pro-GFP activity resulting from treatment with 280 compounds. The dashed red line represents the hit limit calculated as 3 standard deviations away from the mean. (B) Z′ factor analysis per plate screened. Plates 1 to 3 had acceptable Z′ values of ≥0.5, whereas plate 4 was screened in duplicate due to a slightly lower Z′ (average of 0.3). (C) The corresponding CK5Pro-GFP activity and cell viability after treatment with the identified hits. Error bars represent standard deviations. (D) Representative merged (green fluorescent protein [GFP] and Hoechst) images from hits that downregulate CK5Pro-GFP compared with a DMSO-negative control. All cells were treated with progesterone and either hits or with DMSO alone as a negative control.